vs
Side-by-side financial comparison of BILL Holdings, Inc. (BILL) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
BILL Holdings, Inc. is the larger business by last-quarter revenue ($414.7M vs $281.3M, roughly 1.5× Guardant Health, Inc.). BILL Holdings, Inc. runs the higher net margin — -0.6% vs -45.7%, a 45.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 14.4%). BILL Holdings, Inc. produced more free cash flow last quarter ($103.8M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 13.3%).
BILL Holdings, Inc. is an American company based in San Jose, California, that provides automated, cloud-based software for financial operations for small businesses in the United States. A white-labeled, end-to-end payments automation platform, Bill.com Connect is offered to financial institutions as part of their single sign-on online business banking ecosystem.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
BILL vs GH — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $414.7M | $281.3M |
| Net Profit | $-2.6M | $-128.5M |
| Gross Margin | 79.8% | 64.6% |
| Operating Margin | -4.4% | -43.0% |
| Net Margin | -0.6% | -45.7% |
| Revenue YoY | 14.4% | 39.4% |
| Net Profit YoY | -107.7% | -15.8% |
| EPS (diluted) | $-0.03 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $414.7M | $281.3M | ||
| Q3 25 | $395.7M | $265.2M | ||
| Q2 25 | $383.3M | $232.1M | ||
| Q1 25 | $358.2M | $203.5M | ||
| Q4 24 | $362.6M | $201.8M | ||
| Q3 24 | $358.4M | $191.5M | ||
| Q2 24 | $343.7M | $177.2M | ||
| Q1 24 | $323.0M | $168.5M |
| Q4 25 | $-2.6M | $-128.5M | ||
| Q3 25 | $-3.0M | $-92.7M | ||
| Q2 25 | $-7.1M | $-99.9M | ||
| Q1 25 | $-11.6M | $-95.2M | ||
| Q4 24 | $33.5M | $-111.0M | ||
| Q3 24 | $8.9M | $-107.8M | ||
| Q2 24 | $7.6M | $-102.6M | ||
| Q1 24 | $31.8M | $-115.0M |
| Q4 25 | 79.8% | 64.6% | ||
| Q3 25 | 80.5% | 64.7% | ||
| Q2 25 | 80.8% | 65.0% | ||
| Q1 25 | 81.2% | 63.3% | ||
| Q4 24 | 81.6% | 61.6% | ||
| Q3 24 | 82.0% | 61.1% | ||
| Q2 24 | 81.0% | 59.1% | ||
| Q1 24 | 83.0% | 61.2% |
| Q4 25 | -4.4% | -43.0% | ||
| Q3 25 | -5.2% | -37.3% | ||
| Q2 25 | -5.8% | -45.9% | ||
| Q1 25 | -8.1% | -54.6% | ||
| Q4 24 | -6.0% | -62.4% | ||
| Q3 24 | -2.1% | -61.3% | ||
| Q2 24 | -6.5% | -56.8% | ||
| Q1 24 | -8.6% | -59.2% |
| Q4 25 | -0.6% | -45.7% | ||
| Q3 25 | -0.7% | -35.0% | ||
| Q2 25 | -1.8% | -43.0% | ||
| Q1 25 | -3.2% | -46.8% | ||
| Q4 24 | 9.3% | -55.0% | ||
| Q3 24 | 2.5% | -56.3% | ||
| Q2 24 | 2.2% | -57.9% | ||
| Q1 24 | 9.8% | -68.2% |
| Q4 25 | $-0.03 | $-1.01 | ||
| Q3 25 | $-0.03 | $-0.74 | ||
| Q2 25 | $0.02 | $-0.80 | ||
| Q1 25 | $-0.11 | $-0.77 | ||
| Q4 24 | $-0.06 | $-0.90 | ||
| Q3 24 | $0.08 | $-0.88 | ||
| Q2 24 | $0.37 | $-0.84 | ||
| Q1 24 | $0.00 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $378.2M |
| Total DebtLower is stronger | $1.8B | $1.5B |
| Stockholders' EquityBook value | $3.8B | $-99.3M |
| Total Assets | $10.1B | $2.0B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | $378.2M | ||
| Q3 25 | $1.1B | $580.0M | ||
| Q2 25 | $1.0B | $629.1M | ||
| Q1 25 | $1.0B | $698.6M | ||
| Q4 24 | $1.6B | $525.5M | ||
| Q3 24 | $853.5M | $585.0M | ||
| Q2 24 | $985.9M | $933.7M | ||
| Q1 24 | $952.5M | $1.0B |
| Q4 25 | $1.8B | $1.5B | ||
| Q3 25 | $1.9B | $1.1B | ||
| Q2 25 | $1.7B | $1.1B | ||
| Q1 25 | $1.7B | $1.1B | ||
| Q4 24 | $1.7B | $1.1B | ||
| Q3 24 | $914.8M | — | ||
| Q2 24 | $914.0M | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $3.8B | $-99.3M | ||
| Q3 25 | $3.9B | $-354.5M | ||
| Q2 25 | $3.9B | $-305.5M | ||
| Q1 25 | $3.9B | $-250.8M | ||
| Q4 24 | $3.8B | $-139.6M | ||
| Q3 24 | $4.0B | $-60.1M | ||
| Q2 24 | $4.1B | $-1.6M | ||
| Q1 24 | $4.1B | $68.3M |
| Q4 25 | $10.1B | $2.0B | ||
| Q3 25 | $10.2B | $1.3B | ||
| Q2 25 | $10.1B | $1.3B | ||
| Q1 25 | $9.6B | $1.3B | ||
| Q4 24 | $9.7B | $1.5B | ||
| Q3 24 | $9.0B | $1.5B | ||
| Q2 24 | $9.2B | $1.6B | ||
| Q1 24 | $9.1B | $1.7B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $105.3M | $-26.4M |
| Free Cash FlowOCF − Capex | $103.8M | $-54.2M |
| FCF MarginFCF / Revenue | 25.0% | -19.3% |
| Capex IntensityCapex / Revenue | 0.4% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $378.8M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.3M | $-26.4M | ||
| Q3 25 | $96.9M | $-35.4M | ||
| Q2 25 | $83.8M | $-60.3M | ||
| Q1 25 | $99.5M | $-62.7M | ||
| Q4 24 | $78.7M | $-64.5M | ||
| Q3 24 | $88.6M | $-51.1M | ||
| Q2 24 | $78.6M | $-94.0M | ||
| Q1 24 | $66.8M | $-30.3M |
| Q4 25 | $103.8M | $-54.2M | ||
| Q3 25 | $95.6M | $-45.8M | ||
| Q2 25 | $81.0M | $-65.9M | ||
| Q1 25 | $98.4M | $-67.1M | ||
| Q4 24 | $78.3M | $-83.4M | ||
| Q3 24 | $88.6M | $-55.3M | ||
| Q2 24 | $78.4M | $-99.1M | ||
| Q1 24 | $66.8M | $-37.2M |
| Q4 25 | 25.0% | -19.3% | ||
| Q3 25 | 24.1% | -17.3% | ||
| Q2 25 | 21.1% | -28.4% | ||
| Q1 25 | 27.5% | -33.0% | ||
| Q4 24 | 21.6% | -41.3% | ||
| Q3 24 | 24.7% | -28.9% | ||
| Q2 24 | 22.8% | -55.9% | ||
| Q1 24 | 20.7% | -22.1% |
| Q4 25 | 0.4% | 9.9% | ||
| Q3 25 | 0.3% | 3.9% | ||
| Q2 25 | 0.7% | 2.4% | ||
| Q1 25 | 0.3% | 2.2% | ||
| Q4 24 | 0.1% | 9.4% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | 0.1% | 2.9% | ||
| Q1 24 | 0.0% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.35× | — | ||
| Q3 24 | 9.94× | — | ||
| Q2 24 | 10.35× | — | ||
| Q1 24 | 2.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BILL
| Accounts Payable And Accounts Receivable Solutions | $185.9M | 45% |
| Spend And Expense Interchange Revenue | $166.5M | 40% |
| Interest On Funds Held For Customers | $39.5M | 10% |
| Embedded And Other Solutions | $22.8M | 5% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
